Someone can have little pain—and still be at risk. If numb toes make stairs uncertain, or fingertips no longer notice a hot pan, chemotherapy-related neuropathy has become a daily-life safety issue. That deserves attention even when the pain score is zero.
This practical guide focuses on three questions: what should be reported, what can make life safer now, and which treatments actually have human evidence?
What neuropathy can look like
Chemotherapy-induced peripheral neuropathy (CIPN) may cause numbness, tingling, burning, altered temperature sensation, weakness or trouble with fine movements. It can begin during treatment, and sometimes persists after treatment ends. Certain drugs, including taxanes and platinum agents, are recognized contributors. But not every new nerve symptom is caused by chemotherapy: diabetes, vitamin deficiencies, nerve compression and other conditions may need evaluation. The National Cancer Institute’s patient guidance explains how sensory, motor and autonomic symptoms can differ.
A five-part safety plan for everyday life
- Prevent falls: clear walking routes of loose rugs and cords, use adequate lighting, choose stable shoes, and ask about grab bars or bathroom supports.
- Protect skin from injuries: inspect hands and feet for blisters, cuts or burns that reduced sensation might hide. Avoid walking barefoot outdoors or on potentially hot surfaces.
- Take heat seriously: check water temperature with a thermometer or help from someone with reliable sensation; use pot holders and take care with knives.
- Track function, not just pain: tell the team about stumbling, needing railings, dropped objects, trouble buttoning clothes, or interrupted sleep.
- Ask about rehabilitation: physical therapy can address gait, strength and balance; occupational therapy can help with hand function and safer daily routines. Exercises should be adapted to fall risk and treatment status.
These are sensible injury-prevention measures—not therapies proven to repair damaged nerves. The American Cancer Society also emphasizes early reporting and practical adaptations.
When to call your care team
During chemotherapy: report new or worsening numbness, tingling, pain, weakness, or loss of dexterity promptly—ideally before the next infusion—rather than waiting for a routine follow-up. Your team may assess the pattern, other potential causes, and whether to modify treatment. Do not change your chemotherapy schedule or prescribed medicines independently.
Seek emergency assessment now for sudden one-sided weakness or trouble speaking; new severe back pain with leg weakness; loss of bladder or bowel control; or rapidly progressing weakness or inability to walk. These symptoms should not simply be labeled “chemo neuropathy.” New falls, substantial balance deterioration, or sudden functional losses also merit urgent contact with the care team.
Which treatments have evidence?
For preventing neuropathy: the 2020 ASCO guideline did not recommend any medication or supplement for routine CIPN prevention and specifically discouraged acetyl-L-carnitine. Some methods, including limb cooling and compression during selected chemotherapy regimens, are being studied; results vary by regimen and study design, and they should be discussed with the treating team rather than adopted as proven prevention.
For established painful neuropathy: ASCO identified duloxetine as the medication with adequate supporting evidence, but emphasized that average benefit is limited. It targets pain symptoms—not established restoration of sensation, balance or nerve function. Drug interactions, adverse effects and suitability need individual review.
Rehabilitation and integrative approaches: exercise and balance training may support function and confidence. A 2026 systematic review and network meta-analysis of 32 randomized trials (1,612 participants) found a signal favoring acupuncture-based approaches for CIPN-related pain; results were heterogeneous, and the comparative effectiveness of exercise and cryotherapy remained uncertain. This is an emerging symptom-care signal, not proof of nerve regeneration or a replacement for oncology assessment.
The difference between pain relief and protection
A treatment might lower burning pain without restoring protective sensation. A person can therefore feel more comfortable yet still need fall precautions and skin checks. Likewise, a supplement may have a compelling laboratory mechanism without evidence of improving chemotherapy-related nerve outcomes in humans. Distinguishing those outcomes matters when judging clinical studies.
Four questions worth bringing to your next visit
- Could this be treatment-related neuropathy, or are there other causes worth checking?
- Which changes should I report before my next treatment cycle?
- Would a physical or occupational therapy assessment help my walking, balance or hand function?
- Are we trying to reduce pain, avoid injury, preserve function, or all three—and how will we measure progress?
Bottom line: numbness matters even without severe pain. Early reporting, protection from avoidable injuries and individualized oncology decisions are more useful than promising that a supplement will “heal the nerves.”
Explore the evidence
More from Missing Script: Neuropathy in Symptoms & Supportive Care · Alpha-lipoic acid evidence review · Cooling gloves and socks research. Browse more independent evidence reviews in the Evidence Explorer.
Sources: NCI: Peripheral Neuropathy and Cancer Treatment; ASCO guideline update (2020); Kobayashi et al. (2026), systematic review of nonpharmacologic interventions for CIPN-related pain; American Cancer Society: Peripheral Neuropathy.
Missing Script is an independent educational publication. This article is general information, not individualized medical advice. New or worsening neurological symptoms, especially weakness or changes in walking, should be discussed with your cancer care team; red-flag symptoms require emergency assessment. No product or supplement is endorsed here.
Subscribe to Missing Script for two carefully reviewed evidence-focused articles each week.
